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Abstract
Background: The process of obtaining informed consent for participation in randomised controlled trials (RCTs)
was established as a mechanism to protect participants against undue harm from research and allow people to
recognise any potential risks or benefits associated with the research. A number of interventions have been put
forward to improve this process. Outcomes reported in trials of interventions to improve the informed consent
process for decisions about trial participation tend to focus on the ‘understanding’ of trial information. However, the
operationalization of understanding as a concept, the tools used to measure it and the timing of the
measurements are heterogeneous. A lack of clarity exists regarding which outcomes matter (to whom) and why.
This inconsistency between studies results in difficulties when making comparisons across studies as evidenced in
two recent systematic reviews of informed consent interventions. As such, no optimal method for measuring the
impact of these interventions aimed at improving informed consent for RCTs has been identified.
Methods/Design: The project will adopt and adapt methodology previously developed and used in projects
developing core outcome sets for assessment of clinical treatments. Specifically, the work will consist of three
stages: 1) A systematic methodology review of existing outcome measures of trial informed consent interventions;
2) Interviews with key stakeholders to explore additional outcomes relevant for trial participation decisions; and
3) A Delphi study to refine the core outcome set for evaluation of trial informed consent interventions. All stages
will include the stakeholders involved in the various aspects of RCT consent: users (that is, patients), developers
(that is, trialists), deliverers (focusing on research nurses) and authorisers (that is, ethics committees). A final
consensus meeting including all stakeholders will be held to review outcomes.
Discussion: The ELICIT study aims to develop a core outcome set for the evaluation of interventions intended to
improve informed consent for RCTs for use in future RCTs and reviews, thereby improving the reliability and
consistency of research in this area.
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Background
The process of obtaining informed consent for participa-
tion in randomised controlled trials (RCTs) was estab-
lished as a mechanism to help protect participants against
undue harm from research and allow people to recognise
any potential risks or benefits associated with the research
[1]. As part of the invitation to take part, currently, poten-
tial trial participants are usually provided with an informa-
tion leaflet about the trial and given the opportunity to
have any questions answered by a member of the trial
team before indicating their consent by signing agreement
to a series of questions [2]. The adequacy of both the indi-
cation of consent and the broader processes in which it
exists has been called into question.
Much of the research to date investigating the ad-
equacy of the invitation and recruitment process in
RCTs (herein referred to as the RCT decision process)
has tended to focus on aspects relating to how well in-
formed potential participants are or whether they are re-
cruited into the trial. These current ‘outcomes’ of the
RCT decision process, which are fairly ubiquitous in the
available evaluation literature [3–8], do not reflect all the
features considered important by the various stake-
holders in this context [9]. Outcome measures have been
selected largely by the researchers who may not have in-
cluded or consulted consumers and carers (or indeed
other stakeholders) about which outcomes they would
prioritise [8]. In addition to how informed potential par-
ticipants are and whether they are recruited into trials,
other issues such as decision conflict, decision regret,
trust, coercion, resource requirement (time and money)
honesty, autonomy and consumer involvement have
been identified as potentially important [9]. It is thus im-
portant to consider the wider features of RCT decision-
making processes (and the interventions that are de-
signed to improve them) and this broader range of im-
plications. Further research is needed to clarify which
outcomes matter to whom and why to allow consider-
ation of a broader range of outcomes that are of interest
to all relevant decision makers.
As mentioned previously, outcomes reported in trials
of interventions targeting decisions about whether to
participate in a RCT have, to date, tended to focus on
how informed potential participants are (knowledge or
understanding of trial information) and recruitment (or
accrual or enrolment) [7]. Whilst recruitment and asso-
ciated concepts are generally operationalised in a stan-
dardised manner, the conceptualisation of knowledge or
understanding, their operationalisation and the tools
used to measure them, and the timing of their measure-
ment are heterogeneous [4, 8]. Indeed, the measurement
tools for knowledge or understanding are often study-
specific and not well validated [4, 8]. This inconsistency
between study measures results in difficulties when
making comparisons across studies as demonstrated in
two recent systematic reviews of informed consent inter-
ventions [4, 8]. Synthesising outcome data that may have
been collected using tools of different formats, length,
administration and assessment is a significant obstacle
when considering how to bring these studies together
meaningfully in a meta-analysis. The conclusions of the
two reviews that had been previously undertaken are
limited by the heterogeneity of the included outcome
measures [4, 8].
Core outcome sets aim to define a set of outcomes
that should be considered ‘core’ for the evaluation and
reporting of specific interventions or conditions (that is,
the set of outcomes that should always be considered
and ideally measured in any evaluation) [10]. There is a
growing body of literature to provide support for devel-
opment of core outcome sets [10–15]. Specifically, they
are developed using consensus methods involving stake-
holder groups, such as health professional and patients,
so as to ensure that the outcomes being defined are both
clinically and personally relevant for the individuals in-
volved [10, 14]. Generation of a core outcome set is not
expected to be mutually exclusive to the measurement
of other outcomes. However, a core set will foster
greater consistency in outcome reporting between stud-
ies and lead to more meaningful data being available to
contribute to meta-analysis [10, 14]. Moreover, core out-
come sets can minimise the threat of outcome reporting
bias by ensuring consistency between what is measured
and what is reported [10, 14]. Ultimately, they should
improve the overall efficiency and quality of the evidence
on which healthcare decisions can be made [10, 14].
To date the majority of core outcome sets have been
developed for the evaluation of interventions in clinical
conditions. They identify both patient-reported and clin-
ical outcomes as core for particular conditions or inter-
ventions [11–14]. This project is different in that whilst
it aims to develop a core outcome set using established
methodology, the interventions of interest are more
methodological than clinical. The core set will be for the
evaluation of interventions intended to improve the pro-
cesses by which potential participants are invited to par-
ticipate and (particularly) supported to make decisions
about whether to participate in RCTs. (This set of inter-
ventions encompasses informed consent procedures as a
subset). Details of this project have been registered and
included in the Core Outcome Measures in Effectiveness
Trials (COMET) initiative database [15].
Aims and objectives
Aim
The aim of this study is to develop a core outcome set
for the evaluation of interventions that aim to improve
how people make decisions about whether to participate
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in RCTs (of healthcare interventions). The scope is re-
stricted to interventions that target the decisions of
adults deemed to have adequate mental capacity (as de-
fined in the Adults with Incapacity (Scotland) Act 2000
[16], that is, those persons (over 16) who are incapable
of acting, making decisions, communicating decisions,
understanding decisions, or retaining the memory of de-
cisions) and who are deciding, prospectively, for them-
selves about participation in a definitive randomised trial
evaluating the effectiveness of healthcare interventions.
In addition to its role as a core outcome set to evaluate
interventions, the set could also be used as a way to
evaluate the processes used to invite people to take part.
Objectives
The specific study objectives are:
1. To identify a list of outcomes either previously
reported in studies evaluating interventions aiming
to improve how people decide about whether to
participate in RCTs, suggested as relevant in articles
discussing the issue of decisions about participation
in an RCT or articles looking critically at the issue of
informed consent more generally (in research) that
can be seen to have potential relevance to trial
contexts.
2. To explore additional outcomes relevant for
interventions aiming to improve how people decide
whether to participate in an RCT using semi-
structured interviews with stakeholders.
3. To define a core outcome set for evaluation of
interventions to improve decisions about trial




Criteria for consideration of included studies
Types of studies Included studies will have attempted to
identify or investigate what is important in the processes
used to help adults (with capacity) decide whether or not
to participate in randomised clinical trials. For the pur-
poses of this study, the focus will be on decisions to par-
ticipate in so-called ‘effectiveness’ RCTs (that is, ‘studies
(also known as pragmatic studies) that examine interven-
tions under circumstances that more closely approach
real-world practice, with more heterogeneous patient pop-
ulations, less-standardized treatment protocols, and deliv-
ery in routine clinical settings’ [17]). The kinds of studies
that have attempted to identify or investigate what is im-
portant may include both experimental study designs and
exploratory studies. The experimental studies will have
assessed the effects of interventions intended to standard-
ise or improve (aspects of) processes recruiting people to
trials. Studies will include literature reviews with/without
meta-analyses, randomised controlled trials, controlled tri-
als, case series and prospective cohorts. Specifically, the
nature of intervention, findings or discussion (in the in-
cluded study) must focus on a plausible mechanism of ac-
tion which impacts on an aspect that could be considered
important for the decision to participate. Exploratory
studies (using observations, interviews, focus groups and
other methods) that have explored aspects of the RCT de-
cision process (for adults with capacity) will also be in-
cluded. This literature will be supplemented with a critical
analysis of articles that have discussed the ethical aspects
of the processes of recruiting people to research, and any
potentially relevant outcomes for trial participation deci-
sions suggested will also be included.
Exclusion criteria Papers or articles (both experimental
and exploratory) that consider the decision to participate
in research studies that are not definitive effectiveness
RCTs will be excluded.
Search methods for identification of studies
A search strategy has been designed by the Senior Infor-
mation Scientist (CF), refined through discussion with
the Chief Investigator (KG) and informed by previous
work conducted in this area. The search for experimen-
tal studies will focus on interventions targeting the deci-
sion to participate but will be supplemented with a
systematic review of interventions that aim to improve
recruitment. The purpose of this is to be able to include
studies whose primary aim may not be to improve the
decision to participate but may have still measured or
considered outcomes of relevance where there is a
plausible mechanism that impacts an aspect that could
be considered important for the decision to participate,
for example, an open trial design. Specific search strat-
egies have been designed to capture the experimental
studies and exploratory studies separately. The explora-
tory searches will exclude the records retrieved by the
experimental search to avoid duplication of the results.
Searches will be applied to MEDLINE (from 1946),
EMBASE (from 1947) and CINAHL (from 1981) to
the present for both sets of literature, and in addition,
CENTRAL and the Cochrane Methodology Register will
be searched for experimental studies. A formal search
strategy to identify the discursive literature on the ethical
aspects of the processes of recruiting people to RCTs will
be designed. It is likely that some of these articles will also
be identified through reference linking of known texts
(books rather than journals) and of those articles identified
in the quantitative and qualitative search. Detailed search
strategies are provided in Additional file 1. The review will
be reported in accordance with PRISMA guidelines [18].
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A search for additional studies will be undertaken by
checking the references of the included studies. Citation
searches of the included studies will also be performed
using Scopus, Science Citation Index and the Social
Science Citation Index. Experts in the area will be con-
tacted (through email and social media) to identify any
additional studies of importance.
Eligibility of studies Citations identified through the
search will be independently assessed by two reviewers
(KG and a second reviewer). Full text papers will be ob-
tained for those studies that on initial screening are con-
sidered potentially relevant and will be further assessed
for inclusion. Any studies not meeting inclusion criteria
will be excluded. The eligible full text papers will be
assessed independently by two reviewers with a third re-
viewer acting as an arbiter is there is any disagreement.
Reference lists of all included studies will be examined
for further relevant studies.
Data extraction Information from the primary studies
will be extracted independently by two reviewers and
reviewed to assess agreement that all outcomes have been
identified. The following summary data will be extracted
and summarised from each study: study type; study aim;
author details; year and journal of publication; and where
relevant, host study context (for example, condition, trial
design and intervention(s)). Specific details on the out-
come measures used as indicators of important for the
RCT decision and recruitment process will be extracted.
These will include rationale provided by study authors for
the selection of outcomes used; all outcomes reported
(primary, secondary and others); whether the primary out-
come is clearly defined (to allow reproducibility and to in-
clude timing of measurement (time point or period),
person collecting/measuring outcome, and how outcome
was operationalised or measured (for example, validated
tool/measure)); and how the outcome was reported.
Where possible, the same data will be extracted from the
included qualitative studies and additional articles that
discuss outcomes for decisions about RCT participation.
It may be that more discursive papers focus on the con-
ceptualisation and operationalization of potential out-
comes and/or measures (whether previously measured in
this context or not), and these will be extracted and re-
ported as such. The study authors will be contacted if
published data are unavailable or unclear.
Data analysis Data will be summarised and presented
in tabular form. Outcomes will be grouped into outcome
domains following data abstraction and will likely in-
clude (but not be restricted to) areas such as under-
standing, satisfaction, anxiety, decision making, trust
etcetera. Broad outcome domains will be determined
through discussion with the project team and reviewed
by the Advisory Group to assess the suitability of the do-
main name and grouping of outcomes. A framework in-
corporating the outcome domains will be developed,
following previously published examples [12], to aid in
analysis.
Outcomes identified as being assessed with tools
(whether self-reported or not) will be reviewed and
grouped into outcome domains in a similar process to
that previously described. Specifically, we will extract
items verbatim from the identified tools. We will con-
sider the meaning (possible interpretations of) of these
items and compare them for convergence (similarity)
and divergence (difference). Duplicate and very closely
similar items will be removed to create a reduced item
set. The reduced item set will then be systematically
categorised into outcome domains according to the con-
cept they address for example, understanding, satisfac-
tion, anxiety, decision making, trust and domains still to
be determined/confirmed. All individual items will be
mapped to at least one relevant domain. This iterative
process will be performed by the project advisory group.
This is in line with previously published examples [12].
For each broad outcome domain, evaluations of ratio-
nales (and consideration of which outcomes they suggest
are important), variant outcome conceptualisations and
measures used to reflect that domain, the frequency of
selection of individual outcomes (highlighting those
which have been discussed in the literature but not mea-
sured in experimental studies), and the timing of their
implementation will be conducted.
Identification of outcomes of importance to stakeholders
Participant identification and recruitment
Approximately thirty expert stakeholders will be invited
to participate in semi-structured interviews in which
their views on the outcomes identified thus far will be
explored. At this stage, the focus will be on stakeholders
who have some interest in trial participation, decision
making and/or the ethics of recruitment to research. A
range of expertise and perspectives will be sought, and
will likely include (where all non-patient participants will
be providing expert opinion and as much as possible
identified from known existing professional networks)
the following:




4. Social scientists and ethicists with an interest in
trials and/or informed consent, and
5. Psychologists with an interest in communication
research.
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The rationale for including only research nurses in the
Delphi as opposed to other clinical staff is based on the
premise that research nurses, unlike other clinical staff,
are employed primarily to recruit potential participants
to research studies. Linked to this, research nurses are
often the staff responsible for obtaining informed con-
sent from potential trial participants and continuing the
consent process through trial follow-up. As such, they
were deemed the most appropriate clinical stakeholder
group for inclusion in the Delphi process.
A purposive sample of each stakeholder group will be
identified. Sampling will be conducted within each stake-
holder group to provide a balance of participants across
the groups. To ensure a representative balance, sampling
will primarily be informed by the country of residence of
the participant (for non-patient participants) and the
clinical area or population in which they work. The total
of 30 interviews will be made up of approximately six in-
terviews per stakeholder group but will be adjusted ac-
cording to methods of good practice (see below).
Specific organisations, authors of key papers identified
in the literature search (in 3 above), and contacts from
existing professional networks will be invited. Each
group will be identified from the following sources:
1. Patients and advocates from the Scottish Health
Research Register (SHARE), James Lind Alliance and
from health literacy groups (for example,
www.healthliteracy.org.uk).
2. All non-patient groups will first be identified
through known professional networks. If additional
numbers are required, non-patient participants will
be identified as follows:
a) Trialists will be identified through the Society for
Clinical Trials and UK Clinical Trials Units.
b) Research nurses will be invited through the
Scottish Research Nurse and Coordinators
Network (SRNCN), and the NIHR Clinical
Research Network and identified through twitter
(for example, using the #CRNurse).
c) Social scientists will be identified through the
Society for Social Medicine.
d) Ethicists through the Association of Bioethics,
Feminist Approaches to Bioethics Network and
Society for Applied Philosophy.
e) Psychologists through the Society for Medical
Decision Making and the Shared@EACH
facebook page.
The qualitative sample of 30 participants is in line with
numbers reported for the interview stage of previous
Delphi studies and deemed likely to be sufficient for sat-
uration [19, 20]; however, the sample size will be ad-
justed accordingly using a stopping criterion of three if
new opinions continue to emerge from the data (that is,
three consecutive interviews with no additional material
terminates data collection).
Through purposive sampling, a diverse range of partic-
ipants will be included. The aim will be to recruit partic-
ipants with a wide variety of trial experience and diverse
perspectives on features that are important to people
when deciding whether or not to participate in an RCT.
Prospective participants will be sent an invitation letter
and study information in the initial email sent from the
gatekeeper of the list serves or social media contacts. In-
terested parties will be asked to contact the lead researcher
(KG) directly to arrange a convenient time to conduct the
interview. Before the interview commences, the lead re-
searcher (KG) will obtain informed consent, both written
and verbal, from participants. The interviews will be con-
ducted over the phone so as to allow inclusion of partici-
pants across a wide geographic area and will last between
20 and 60 minutes. All interviews will be audio-recorded
and transcribed for analysis.
Date collection
A summary of findings from the literature review will be
shared in advance. A definition and interpretive notes
will be developed by the Advisory Group for each of the
outcome domains and associated outcomes. These will
be provided to aid participants understanding.
Participants will be asked to comment generally on
whether and why particular features are important and
how they conceptualise and assess the importance of
these outcomes, for example, why potential participants’
knowledge about one aspect of the trials is normatively
or practically more significant than knowledge about
other aspects (or outcomes other than knowledge). Spe-
cifically, informants will be asked to reflect on the ap-
plicability of identified outcomes, suggest additional
outcomes of relevance and why these outcomes could be
important in a trial context and identify which outcomes
they would consider core and why. This will allow iden-
tification of outcomes that, as yet, have not been consid-
ered or measured in empirical studies of interventions to
improve the decision-making process for trial participa-
tion, or discussed in literature on research ethics. All in-
terviews will be audio-recorded and transcribed.
Data analysis
The interview analysis will begin during data collection,
with the initial data analysis of preliminary interviews be-
ing used to inform the subsequent data collection. This
process allows development and refinement of key topics
for exploration in subsequent interviews. Interview data
will be coded and compared through a process of constant
comparison [21] to provide a summary of the key
points about what stakeholders consider important in
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this context. Each stakeholder group will be analysed in
parallel, but within and across group analysis will be
conducted to explore areas of convergence and areas of
divergence. The transcripts will be imported into NVivo
(a qualitative analysis software, version 10, 2013:QSR
International) and analysed using the framework ap-
proach, which is an established interpretive approach that
uses constant comparison techniques [22, 23]. The frame-
work approach is made up of five stages: familiarisation
with the data, development of a thematic framework,
indexing data, devising thematic charts, and mapping and
interpreting data [23]. The codes identified and the associ-
ated data assigned to them from the transcripts will be
reviewed by a second member of the project team. Specif-
ically, the analysis will be oriented to address the aim of
identifying the range of outcomes that might be consid-
ered important and the reasons used to justify assessment
of them as important.
Ethical approval for the qualitative interviews with
stakeholders has been obtained. This study was ap-
proved by the National Research Ethics Service Commit-
tee London-Chelsea (REC reference 15/LO/0375).
Define core outcome set for evaluation of trial informed
consent interventions
Overview
To identify outcomes of importance across groups in-
volved directly in decisions about participation in RCTs
(for example, designers (trialists and lead clinicians),
recruiters (research nurses), potential participants and
authorisers (ethics committees), a Delphi consensus sur-
vey approach, employing up to three rounds of rating, will
be used. The use of a Delphi will allow participants re-
sponses to be obtained without influence from others and
allows analysis based on individual stakeholder groups,
giving equal weighting to all participants. An overview of
the Delphi exercise is given in Additional file 2.
Identification of potential outcomes
The list of potential outcomes generated from the system-
atic review and interviews will form the basis of the inter-
national Delphi survey to refine the items into a core
outcome set. The outcomes will be listed individually but
also grouped into relevant domains (as in Data analysis in
3.1.2) so as to assist in interpretation and use of the Delphi
survey. The outcome list will be reviewed by the Advisory
Group (composed of content and methodology experts in
the fields of decision making, ethics and clinical trials)
specifically for comprehension but also for suitability of
the outcome domain structure and groupings.
Participants
Stakeholders will be invited to participate in the Delphi
survey through email distribution lists, social media or
direct contact. Potential participants will be contacted
by a gatekeeper on behalf of the research team. Each
stakeholder group will be identified from the following
sources:
1. Patients and advocates from the Scottish Health
Research Register (SHARE), James Lind Alliance,
and from health literacy groups (for example,
www.healthliteracy.org.uk).
2. All non-patient groups will first be identified
through known professional networks. If additional
numbers are required, non-patient participants will
be identified as follows:
a) Trialists will be identified through the Society for
Clinical Trials and UK Clinical Trials Units.
b) Research nurses will be invited through the
Scottish Research Nurse and Coordinators
Network (SRNCN), and the NIHR Clinical
Research Network and identified through twitter
(for example, using the #CRNurse).
c) Social scientists will be identified through the
Society for Social Medicine.
d) Ethicists through the Association of Bioethics,
Feminist Approaches to Bioethics Network and
Society for Applied Philosophy.
e) Psychologists through the Society for Medical
Decision Making and the Shared@EACH
facebook page.
f ) Ethics committee chairs through the National
Research Ethics Service and known contacts at
Institutional Research Boards (IRBs).
Justifications for sample size included in this survey
are discussed below in section 5.7. Invitation letters de-
scribing the Delphi survey will be sent through the email
distribution list with interested parties being asked to
complete the Delphi questionnaire, which will be an on-
line questionnaire accessed through an embedded web
link in a direct email.
The number of participants completing the question-
naire will be recorded, and this will be compared to
completion throughout subsequent rounds of the Delphi
to assess attrition. In addition, the computer software
will record who accesses the Delphi website but does
not go on to complete the scoring.
The opening page for the Delphi survey will provide a
brief introduction of the aim of the study and will re-
mind participants of the importance of completing all
rounds of the process. Reminder emails will be sent to
non-responders at each round. Participants who agree to
participate will be asked to register their details online
(including specifying which stakeholder group they are
associated), which will generate a unique identifier
against which their data will be stored and reminder
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emails for non-response will be generated. Participants
will not be able to identify other participants or others
individual responses. Explicit consent will not be sought
for the Delphi survey. Instead, consent will be implicit
by completion and return of the questionnaire. However,
the questionnaire will include a section to state that par-
ticipants are happy to be contacted again in the future
for additional research activities linked to this stage, that
is, the final discussion group.
Ethical approval for the Delphi survey with stake-
holders has been obtained.
Delphi survey
Delphi round 1
The survey will be developed into a web-based applica-
tion using software (known as COMET Delphi Manager)
developed by Programmers with experience of deve-
loping online Delphi surveys and who work closely with
the COMET Initiative (www.comet-initiative.org/). A be-
spoke website (modified from existing templates) and
unique web link will be created. During the first round
of the online questionnaire, the participant’s name and
email address will be requested. This information will be
stored in a separate database and used to generate the
unique identifier. The first question will ask each re-
spondent to identify their stakeholder group(s) and to
specify their experience of RCTs. Participants will be
asked to complete each round of the Delphi survey
within 3 weeks of receiving the email for each round. A
reminder email will be sent to non-responders at the
end of week 2 to prompt their completion of the survey.
Round 1 survey format
The survey will be presented through an online plat-
form, as described above. A definition (as determined by
the Advisory Group) of each of the outcome domains
and associated outcomes will be provided to aid partici-
pant understanding. Round 1 content will include a list of
outcomes for scoring that is ordered alphabetically by do-
main and a free text box to allow participants to add any
additional outcomes and provide an associated score. The
respondents will be asked to consider the following:
Think about the process of being invited to take part
in a clinical trial. How important do you think each
item listed below would be in judging how well that
process had been conducted?
As defined in other Delphi surveys for developing core
outcome sets, participants will be asked to score each of
the listed items using the Grading of Recommendations,
Assessment, Development and Evaluations (GRADE)
scale of 1 to 9 [11, 13, 23]. The scale will be annotated
to illustrate that a score of 1 to 3 is interpreted as having
‘limited importance’, 4 to 6 as ‘important but not critical’
and 7 to 9 as ‘critical’ [23]. As outlined above, a free text
box will be provided for participants to include any add-
itional outcomes and associated scores.
Analysis of round 1
Descriptive statistics will be used to summarise the results
from each round. For each outcome, the distribution of
scores (frequency distribution, the median and interquar-
tile range) will be summarised by stakeholder group
alongside the total number of participants who scored the
outcome. Any new additional outcomes listed by partici-
pants in round 1 will be reviewed and coded by two mem-
bers of the study team to ensure they are independent
from those listed, with a third reviewer acting as an arbiter
if there is disagreement. Participants will be instructed to
rate all outcomes on their own merit even if they appear
similar. All outcomes will be carried forward to round 2.
Response rate in round 1
Following the completion of round 1, the results will be
presented for the research team as the total number of
registrations to the website, the number of participants
who have completed round 1, the total number of par-
ticipants in each stakeholder group and the number of
respondents as a percentage of those invited by stake-
holder group.
Round 2 assumes sufficient numbers respond to round
1 across each of the stakeholder groups. If there are in-
adequate numbers for one or more stakeholder groups,
the Advisory Group will be consulted. For the purposes
of this project, inadequate numbers have been prede-
fined by the project team as fewer than 20 in any stake-
holder group. The rationale for this lower limit has been
informed by a recent study by Harman et al. who used a
lower limit of 10 in any stakeholder group [11]. As we
are randomising participants to one of two ways of re-
ceiving feedback, the lower limit for the ELICIT study is
20. Those who have not taken part in round 1 (that is,
did not score outcomes) will not be invited to participate
in further rounds.
Delphi round 2
Round 2 of the Delphi survey will also be presented on-
line. During Round 2, participants will be randomised to
one of two groups for the type of feedback they receive, as
conducted in previous core outcome set projects [12, 13].
The first group will receive feedback at the level of their
own individual stakeholder group, whereas the second
group will receive feedback from each of the stakeholder
groups. Participants will be presented with feedback
(number of respondents and distribution of scores across
the 1-9 scale) relevant for their particular randomised
group and personalised feedback relating to their previous
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score for each outcome. Participants will be asked to con-
sider their score within the context of the scores of others
in their randomised group and then rescore the outcome
again, using the nine- point scale.
Analysis of round 2
The total number of participants invited to participate in
round 2 will be recorded and compared to the total num-
ber of round 2 responders (and compared for response
bias between the two randomised feedback groups). For
each outcome, the distribution of scores will be sum-
marised across stakeholder groups. All outcomes will be
carried forward to round 3.
Delphi round 3
In the final online round of the Delphi, participants will be
presented with the distribution of scores for each outcome
for each of the stakeholder groups and reminded of their
personal score from Round 2. Participants will then be
asked to rescore all outcomes and consider whether, and
why, they should be included in a core outcome set.
Analysis of round 3
The total number of participants invited to round 3 will
be recorded and compared to the total number of round
3 responders. For the final analysis, for each outcome,
the number of participants who scored the item and the
distribution of scores will be summarised, alongside the
number of respondents who scored the items across all
three rounds. For each outcome, the proportion of re-
spondents scoring 1 to 3, 4 to 6 and 7 to 9 on the Likert
scale will be calculated for each item. Each outcome will
be classified as: ‘consensus in’ (that is, consensus that
the outcome should be included in a core set), ‘consen-
sus out’ (that is, consensus that the outcome should not
be included in a core set) or ‘no consensus’ (that is,
items that are equivocal and require further research for
clarification), according to the classifications in Table 1.
Justification for these levels and definition of consen-
sus are given below in section 5.6.
Consensus meeting
The final phase of the consensus study will be a face-to-
face meeting with key participants from the Delphi exercise
and preliminary interviews. The main aim of the consensus
meeting will be to determine consensus (in or out) for
those items that exhibited no consensus.
Potential participants will have been identified through
earlier rounds of the research and will have consented to
be contacted again for additional stages of the project.
Informed consent will be obtained (by the lead re-
searcher) from participants before initiation of the dis-
cussion group. The discussion group will be face-to-face
and will be facilitated by the research team. The discus-
sion will be conducted at a location agreed-upon as mu-
tually convenient by most participants and will likely last
up to 3 hours. The group discussion will be audio-
recorded and transcribed for analysis.
The results from the Delphi survey will be presented,
with a focus for discussions being those outcomes for
which there was disagreement in Round 3 and to further
validate and agree on a final list of outcomes that will
constitute the ‘core outcome set’. The final format of the
consensus meeting will be determined based on a review
of experiences from similar projects and the percentage
agreement between the group and stakeholder overall
scores, which will help to identify areas of divergence or
significant agreement. We will document the discussions
during the consensus meeting paying particular atten-
tion to any gaps or minority concerns about the list that
achieved consensus so as to reflect on any potential limi-
tations. These discussions will also provide further op-
portunity to hear a refined discussion of the reasoning
for regarding some outcome domains as important. By
the end of the consensus meeting, ‘what’ outcomes to
measure should have been identified. Questions about
‘how’ to measure them (that is, which instruments to
use) may still require further work, but this will not pre-
clude the inclusion of any outcome (whether currently
measurable or not) in the final recommended core out-
come set. Determining ‘how’ to measure the identified
outcome is outside the scope of this study.
Justification for definition of consensus
With reference to the Delphi survey, the definition of
consensus used in the ELICIT study to determine inclu-
sion of an outcome will be based on previously pub-
lished examples [11, 13]. These definitions (see Table 1)




Consensus in Consensus that outcome should be included in the core outcome set ≥70 % scoring 7 to 9 AND <15 % scoring 1 to 3
Consensus out Consensus that outcome should not be included in the core
outcome set
≥70 % scoring 1 to 3 AND <15 % scoring 7 to 9
No consensus Uncertainty about importance of outcome Anything else and no new compelling reasons in the
comments boxes regarding why.
(taken from Harman et al. 2013 and Waters et al. 2014 [10, 12])
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are built on the premise that an outcome should be in-
cluded in the core set if the majority agree on its critical
importance and only a minority consider it unimportant.
Conversely, for exclusion of an outcome, the majority
must agree on its lack of importance with only a minor-
ity considering it critical. The decision regarding thresh-
olds for inclusion and exclusion in Delphi studies varies,
with no defined rules on limits [10–14]. However, al-
though subjective, the levels described in the ELICIT
study have been implemented in other Delphi studies to
define core outcome sets [10–14]. To minimise bias, the
definition of consensus should always be specified at
study outset and not post hoc based on preferences of
the study team.
Statistical considerations
There is currently no standard method for determining
sample size calculations for Delphi studies. However, there
is emerging evidence in the literature that expert panels of
around 20 can provide stable results [24]. As such, a prag-
matic approach is adopted taking into consideration the
access to participants and interest from those invited,
manageability of data and representativeness. Through
discussion with the project team, the minimum sample
size required for analysis was determined to be 20 partici-
pants per stakeholder group. Therefore, to allow for 50 %
attrition between the three rounds, a minimum of 80 par-
ticipants per stakeholder group will be invited to partici-
pate in the Delphi survey; however, efforts will be made to
maximise response rates across stakeholder groups so as
to ensure that attrition bias is minimal.
Discussion
To date, no core outcome set for the evaluation of inter-
ventions for improving processes of inviting people to
participate in RCTs has been published. The develop-
ment of a core outcome set in this methodological area
aims to improve the conduct, interpretation and com-
parison of past and future studies by minimising hetero-
geneity across studies and reducing the potential risk of
outcome selection and reporting bias in studies of this
type. Determining which outcomes to measure for evalu-
ation of RCT recruitment processes and interventions
will also require further reflections on how to measure
these core outcomes and will provide key areas for fu-
ture research. The ELICIT study will involve multiple
key stakeholders through several stages of the study to
ensure that any core outcome set defined is fit for pur-
pose and well accepted in future research, both in the
UK and internationally.
Trial status
Overall, the protocol does not report a trial but rather
development of a core outcome set for use in future
trials of interventions to improve informed consent.
However, there is a randomised component to the
Delphi survey (see section 5.4.2a). This project is cur-
rently in the set-up phase.
Additional files
Additional file 1: Search strategies. Search strategies for each of the
individual platforms searched. (DOCX 23 kb)
Additional file 2: Delphi Overview. Figure providing an overview of
the Delphi process. (DOCX 32 kb)
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